News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Upstate Awarded $207k Grant From National Cancer Institute



10/19/2005 5:11:40 PM

CHARLOTTESVILLE, Va., June 7 /PRNewswire/ -- Upstate, in collaboration with the University of Virginia Health Science Center, has been granted a Phase I STTR (Small Business Technology Transfer) award in the amount of $207,522 by The National Cancer Institute in Bethesda, MD. The grant is to fund initial experiments to develop novel small molecule inhibitors of histone acetyltransferase enzymes (HATs), important regulators of genome function.

Abberant HAT function is common in several types of cancer, and the development of inhibitors to HATs could lead to future progress in cancer therapeutics. Cancer primarily involves the dysregulation of cell proliferation and cell signaling. Cell signaling, Upstate's core business, is a common theme in cancer research and drug discovery.

About the Grant

Federal agencies with qualifying research and development budgets are required to allocate 0.3 percent to cooperative research. The STTR award mandates that work be conducted jointly with a business performing at least 40 percent of the work and a non-profit research institution performing at least 30 percent. Under the grant structure, positive peer reviewed results at the end of Phase I (next year) could lead to an additional grant approval for Phase II and a dramatic increase in funding.

"We are extremely pleased to have this opportunity to work with the University of Virginia Health Science Center on this project. This type of research can lead to the development of novel cancer treatment protocols," said James Bone, Ph.D., a Research and Development Manager for Upstate. While Upstate and UVA have long had a relationship, this is the first time the two will perform joint research.

Upstate is the leading supplier of innovative cell signaling products, technology, platforms and services. Founded in 1988, Upstate provides researchers at pharmaceutical and biotechnology companies, universities and government agencies with advanced tools to accelerate life science research and drug discovery. Upstate's global reach includes six locations in the U.S. and Europe with key technology centers in its Charlottesville, VA headquarters; Lake Placid, NY; and Dundee and Cambridge in the U.K.

CONTACT: Reese A. Nank, APR, of Reputations PR and Marketing, +1-410-218-9121, or reputationspr@cox.net, for Upstate.

Upstate

CONTACT: Reese A. Nank, APR, of Reputations PR and Marketing,+1-410-218-9121, or reputationspr@cox.net, for Upstate


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES